Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of retigabine in adults with partial-onset seizures
NL-OMON34147Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of retigabine in epilepsy and Focal onset seizure, sponsored by GSK. Primary endpoint: Adverse events. Started Jul 2011; status: active, not recruiting.
02
Drugs
retigabine
03
Conditions
epilepsyFocal onset seizure
Beyond the preview
Go deeper on NL-OMON34147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34147.